08/19/2020
Gary H. Lyman, MD, MPH, FASCO, FRCP, FACP; David R. Doody, MS; Shasank Chennupati, PharmD, MPH; Eric J. Chow, MD, MPH; Lena E. Winestone, MD, MSHP; Henry J. Henk, PhD; Pamela Morin, MBA; Jennifer J. Wilkes, MD, MSCE
Abstract: The therapeutic landscape for chronic myeloid leukemia (CML) has evolved substantially over the past decade, most notably with the introduction of second- and third-generation tyrosine kinase inhibitors...
Abstract: The therapeutic landscape for chronic myeloid leukemia (CML) has evolved substantially over the past decade, most notably with the introduction of second- and third-generation tyrosine kinase inhibitors...
...
